Celularity (NASDAQ:CELU) Stock Price Up 1.3% on Analyst Upgrade

Key Points

• Celularity's stock price rose by 1.3% after an upgrade from Wall Street Zen, changing its rating from sell to hold.
• WBB Securities initiated coverage on Celularity with a moderate buy rating and a price target of $6.00.
• Institutional investors have increased their stakes significantly, with Bank of America Corp DE raising its holdings by 1,538.1% during the second quarter.

Shares of Celularity, Inc. (NASDAQ:CELU - Get Free Report) rose 1.3% on Monday after Wall Street Zen upgraded the stock from a sell rating to a hold rating. The company traded as high as $4.00 and last traded at $3.84. Approximately 36,127 shares changed hands during trading, a decline of 55% from the average daily volume of 80,518 shares. The stock had previously closed at $3.79.

Separately, WBB Securities started coverage on Celularity in a research report on Monday, August 18th. They set a "moderate buy" rating and a $6.00 price objective on the stock.

Institutional Investors Weigh In On Celularity

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CELU. Acadian Asset Management LLC purchased a new position in shares of Celularity in the 1st quarter worth approximately $34,000. XTX Topco Ltd boosted its stake in Celularity by 106.4% during the second quarter. XTX Topco Ltd now owns 21,452 shares of the company's stock worth $42,000 after buying an additional 11,057 shares during the period. Bank of America Corp DE increased its position in Celularity by 1,538.1% during the second quarter. Bank of America Corp DE now owns 37,300 shares of the company's stock valued at $73,000 after acquiring an additional 35,023 shares during the last quarter. Two Sigma Investments LP purchased a new stake in shares of Celularity in the fourth quarter valued at $93,000. Finally, Valmark Advisers Inc. bought a new stake in shares of Celularity in the 2nd quarter worth about $98,000. 19.02% of the stock is currently owned by hedge funds and other institutional investors.

Celularity Stock Performance

The stock has a market capitalization of $94.36 million, a PE ratio of -1.49 and a beta of 0.79. The business's 50 day moving average is $2.92 and its 200 day moving average is $2.15. The company has a current ratio of 0.38, a quick ratio of 0.28 and a debt-to-equity ratio of 4.07.

Celularity (NASDAQ:CELU - Get Free Report) last announced its quarterly earnings data on Friday, August 29th. The company reported ($1.02) earnings per share (EPS) for the quarter. The firm had revenue of $5.74 million during the quarter. Celularity had a negative return on equity of 271.88% and a negative net margin of 106.77%.

Celularity Company Profile

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.